Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Follow Oxford Nanopore Technologies at:

Oxford Nanopore Technologies

Oxford Nanopore Technologies, founded in 2005, makes a novel generation of DNA/RNA sequencing technology that provides rich data, is fast, accessible and easy to use.  Their goal is to disrupt the way that biological analyses are currently performed, and open up new applications that have a profound, positive impact on society.

Oxford Nanopore’s sequencing technology is used across a spectrum of biological research including human genetics, cancer research, plant/agricultural/food science, environmental, and pathogen analysis.  The technology is used in more than 70 countries to sequence SARS-CoV-2, the virus that causes COVID-19.   Nanopore sequencing offers real-time analysis (for rapid insights), in fully scalable formats from pocket to population scale, that can analyse native DNA or RNA and sequence any length of fragment to achieve short to ultra-long read lengths

Headquartered in Oxford, UK, the company has satellite offices in Cambridge (UK), New York, Cambridge, San Francisco (US), Singapore, Shanghai, Beijing, and sells to nearly 100 countries.

 

Amadeus contact

Andrea Traversone